Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Patient Recruitment Main Factor in Lengthy Oncology Clinical Trial Durations

Published: Wednesday, February 20, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
As a company’s oncology clinical trial progresses from Phase 1 to Phase 3, trial duration typically lengthens the difference between projected and actual patient enrollment increases.

“In most cases, it’s the patient recruitment challenges that delay clinical trials in oncology,” said Ryan McGuire, senior research analyst at Cutting Edge Information. “And if two companies are running competing clinical trials, then enrolling patients becomes even more of a challenge.”

Cutting Edge Information’s study, “Oncology Clinical Trials: Drug Development Resources and Case Studies,” found that across all phases of oncology clinical trials, the two main factors impacting duration are the level of difficulty of trial-specific patient recruitment and the number of patient visits required by a trial. During Phase 1 and Phase 2 trials, these durations average between 27.5 and 26.1 months respectively. The longest trial durations during these phases fall between 48 and 50 months. To compare, the average length of a Phase 3 trial, according to surveyed trial profiles, is approximately 41 months; with the longest Phase 3 trial topping 81 months.

Some targeted patients may already be participating in other clinical trials depending on the specific area of oncology studied. In the areas where there are more available treatment options, patients may prefer the current standard of care as opposed to unproven investigative clinical trials. Cutting Edge Information found that drug companies can lessen the patient recruitment challenge in geographic areas where clinical trials are one of the few low-cost treatment options available for afflicted patients.

“Oncology Clinical Trials: Drug Development Resources and Case Studies” (http://www.cuttingedgeinfo.com/research/clinical-development/oncology-clinical-trials/) features detailed data on clinical development for oncology treatment including specific methods for allocating the correct resources in Phase 3. The research also highlights up-to-date metrics illustrating clinical costs for oncology trials, one of the largest areas of study for the pharmaceutical industry. Use this report to:
•    Explore areas of higher activity for different types of cancer drug development
•    Get a robust picture of each phase’s challenges and costs.
•    Determine the cost per patient and other critical cost drivers


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!